FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2292657992> ?p ?o ?g. }

• W2292657992 endingPage "195" @default.
• W2292657992 startingPage "188" @default.
• W2292657992 abstract "Abstract Background Pituitary carcinomas (PC) and atypical pituitary adenomas (APA) are rare variants of pituitary tumors for which no evidence-based treatment currently exists. We sought to determine whether temozolomide represents an effective chemotherapeutic option for patients with PC and APA. Methods A systematic review was performed using all published cases of PC and APA treated with temozolomide, and for which information on treatment regimen, clinical response, and survival could be identified. The primary goal of this analysis was to describe overall survival and progression-free survival among PC and APA patients after temozolomide treatment. Secondary goals included assessment of response rate and biomarkers of response. Results We identified 57 cases and obtained follow-up data on 54 patients (31 APA and 23 PC) for analysis. Estimates of 5-year progression-free survival and overall survival were 21.9% and 57.4% for patients with APA and 36.1% and 56.2% for patients with PC. Among those who responded to temozolomide, overall survival was marginally statistically significantly greater for patients on long-term temozolomide therapy compared with those who were not (5-year overall survival 91.7% vs 54.1%, P = .08); Progression-free survival results were similar but not statistically significant. The objective response rate was 48.4% for patients with APA and 65.2% for patients with PC. Stable disease occurred in 29% of APA and 17.4% of PC patients. Neither histology nor expression of Ki-67 correlated with response; however, negative O6-methylguanine-DNA methyltransferase staining was strongly related to response to temozolomide in patients with APA (P &lt; .001). Conclusions Temozolomide is an effective treatment of both PC and APA, and long-term treatment can be considered for particularly aggressive cases." @default.
• W2292657992 created "2016-06-24" @default.
• W2292657992 creator A5020583341 @default.
• W2292657992 creator A5062667375 @default.
• W2292657992 creator A5081186975 @default.
• W2292657992 date "2015-11-12" @default.
• W2292657992 modified "2023-10-09" @default.
• W2292657992 title "Temozolomide treatment of pituitary carcinomas and atypical adenomas: systematic review of case reports" @default.
• W2292657992 cites W1607070363 @default.
• W2292657992 cites W1626154384 @default.
• W2292657992 cites W1965579078 @default.
• W2292657992 cites W1988787595 @default.
• W2292657992 cites W1991496729 @default.
• W2292657992 cites W1998829259 @default.
• W2292657992 cites W2003738224 @default.
• W2292657992 cites W2004031828 @default.
• W2292657992 cites W2005619353 @default.
• W2292657992 cites W2005940712 @default.
• W2292657992 cites W2015376162 @default.
• W2292657992 cites W2016854939 @default.
• W2292657992 cites W2019006916 @default.
• W2292657992 cites W2019911161 @default.
• W2292657992 cites W2019929802 @default.
• W2292657992 cites W2030950835 @default.
• W2292657992 cites W2031772971 @default.
• W2292657992 cites W2041005868 @default.
• W2292657992 cites W2042673956 @default.
• W2292657992 cites W2043155677 @default.
• W2292657992 cites W2051452797 @default.
• W2292657992 cites W2052655103 @default.
• W2292657992 cites W2063431624 @default.
• W2292657992 cites W2067294558 @default.
• W2292657992 cites W2071027624 @default.
• W2292657992 cites W2075882488 @default.
• W2292657992 cites W2096287682 @default.
• W2292657992 cites W2097036233 @default.
• W2292657992 cites W2100396774 @default.
• W2292657992 cites W2101150095 @default.
• W2292657992 cites W2108656068 @default.
• W2292657992 cites W2112719621 @default.
• W2292657992 cites W2116242713 @default.
• W2292657992 cites W2119175953 @default.
• W2292657992 cites W2124294968 @default.
• W2292657992 cites W2125647022 @default.
• W2292657992 cites W2126937059 @default.
• W2292657992 cites W2140589404 @default.
• W2292657992 cites W2148977460 @default.
• W2292657992 cites W2151409134 @default.
• W2292657992 cites W2152914748 @default.
• W2292657992 cites W2159121641 @default.
• W2292657992 cites W2330508951 @default.
• W2292657992 cites W4293529598 @default.
• W2292657992 doi "https://doi.org/10.1093/nop/npv059" @default.
• W2292657992 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4986928" @default.
• W2292657992 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27551432" @default.
• W2292657992 hasPublicationYear "2015" @default.
• W2292657992 type Work @default.
• W2292657992 sameAs 2292657992 @default.
• W2292657992 citedByCount "45" @default.
• W2292657992 countsByYear W22926579922016 @default.
• W2292657992 countsByYear W22926579922017 @default.
• W2292657992 countsByYear W22926579922018 @default.
• W2292657992 countsByYear W22926579922019 @default.
• W2292657992 countsByYear W22926579922020 @default.
• W2292657992 countsByYear W22926579922021 @default.
• W2292657992 countsByYear W22926579922022 @default.
• W2292657992 countsByYear W22926579922023 @default.
• W2292657992 crossrefType "journal-article" @default.
• W2292657992 hasAuthorship W2292657992A5020583341 @default.
• W2292657992 hasAuthorship W2292657992A5062667375 @default.
• W2292657992 hasAuthorship W2292657992A5081186975 @default.
• W2292657992 hasBestOaLocation W22926579921 @default.
• W2292657992 hasConcept C104317684 @default.
• W2292657992 hasConcept C126322002 @default.
• W2292657992 hasConcept C143998085 @default.
• W2292657992 hasConcept C2776694085 @default.
• W2292657992 hasConcept C2777389519 @default.
• W2292657992 hasConcept C2779527866 @default.
• W2292657992 hasConcept C2780739268 @default.
• W2292657992 hasConcept C2781413609 @default.
• W2292657992 hasConcept C33288867 @default.
• W2292657992 hasConcept C55493867 @default.
• W2292657992 hasConcept C71924100 @default.
• W2292657992 hasConcept C86803240 @default.
• W2292657992 hasConcept C91965660 @default.
• W2292657992 hasConceptScore W2292657992C104317684 @default.
• W2292657992 hasConceptScore W2292657992C126322002 @default.
• W2292657992 hasConceptScore W2292657992C143998085 @default.
• W2292657992 hasConceptScore W2292657992C2776694085 @default.
• W2292657992 hasConceptScore W2292657992C2777389519 @default.
• W2292657992 hasConceptScore W2292657992C2779527866 @default.
• W2292657992 hasConceptScore W2292657992C2780739268 @default.
• W2292657992 hasConceptScore W2292657992C2781413609 @default.
• W2292657992 hasConceptScore W2292657992C33288867 @default.
• W2292657992 hasConceptScore W2292657992C55493867 @default.
• W2292657992 hasConceptScore W2292657992C71924100 @default.
• W2292657992 hasConceptScore W2292657992C86803240 @default.
• W2292657992 hasConceptScore W2292657992C91965660 @default.

• next